Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4213663 | 0.90 | LMNA (0.46) | ALDH1A1LMNASMN1; SMN2KDM4EKMT2A | |
| SCHEMBL3145722 | 0.85 | LMNA (0.46) | ALDH1A1LMNASMN1; SMN2KDM4EKMT2A | |
| SCHEMBL6666505 | 0.82 | LMNA (0.50) | ALDH1A1LMNASMN1; SMN2KDM4EMAOB | |
| SCHEMBL15267352 | 0.79 | ALDH1A1 (0.55) | ALDH1A1LMNASMN1; SMN2KDM4EMAOB | |
| SCHEMBL7052410 | 0.79 | LMNA (0.43) | ALDH1A1LMNASMN1; SMN2KDM4EMAOB | |
| SCHEMBL7052412 | 0.79 | IDO1 (0.52) | ALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL12872390 | 0.76 | LMNA (0.41) | ALDH1A1LMNASMN1; SMN2KDM4EMAOB | |
| SCHEMBL9068579 | 0.76 | LMNA (0.41) | ALDH1A1LMNASMN1; SMN2KDM4EKMT2A | |
| SCHEMBL10061345 | 0.76 | MAOB (0.55) | ALDH1A1SMN1; SMN2KDM4EMAOBHTT | |
| SCHEMBL8579457 | 0.76 | LMNA (0.46) | ALDH1A1LMNASMN1; SMN2KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280855-A1 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles | NYCOMED GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
| EP-1904454-A2 | PROCESS FOR THE PRODUCTION OF INTERMADIATES FOR THE PREPARATION OF TRICYCLIC BENZIMIDAZOLES | Nycomed GmbH (DE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006136552-A2 | PROCESS FOR THE PRODUCTION OF INTERMADIATES FOR THE PREPARATION OF TRICYCLIC BENZIMIDAZOLES | NYCOMED GMBH (DE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280855-A1 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles | CYP1B1, CYP1A1, CYP3A4 | ALDH1A1 76/4885LMNA 2133/4885SMN1; SMN2 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.